Clinical Pharmacology of Xenon

Y. Nakata,T. Goto,S. Morita

DOI: https://doi.org/10.1097/00004311-200104000-00007

International Anesthesiology Clinics

Abstract:The anesthetic gases and vapors in routine use have undesirable side effects on both patients and medical and nursing staff and are a source of environmental pollution. For example, nitrous oxide (N2O) can induce megaloblastic bone marrow changes and myeloneuropathy and can also disturb the earth’s ozone layer. The search continues, therefore, for an inhaled agent that meets all the requirements for an anesthetic agent but has none of these disadvantages. Xenon (Xe), an inert gas with anesthetic properties, has attracted renewed interest because it possesses many of the characters of an ideal anesthetic, although it was first described as an anesthetic agent in 1940s. Its minimum alveolar concentration (MAC) is 63% to 73% in humans, suggesting that it is more potent than N2O (MAC of 104%). 8,9 Xe has a blood-gas partition coefficient of 0.115, which is significantly lower than that of other clinically used inhaled anesthetics. For example, the bloodgas partition coefficients of N2O, sevoflurane, and desflurane are 0.47, 0.65, and 0.42, respectively. Xe is nonexplosive, nonpungent, and odorless. Whereas N2O is fetotoxic, Xe is devoid of teratogenic effects. 3,5 Because Xe is an inert gas, it hardly undergoes biotransformation. Furthermore, unlike other inhaled anesthetics, it is environmentally friendly because it is prepared by fractional distillation of atmospheric air. Although its relatively high cost renders it of limited clinical use, these properties, combined with the trend toward low-flow or closed-circuit anesthesia techniques, have caused anesthesiologists to reconsider the use of Xe. Little is known about the pharmacology of Xe that can be applicable to clinical anesthesia practice. There are a number of clinical studies on the pharmacology of Xe, and most of these have been published by our